Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.
JCO Precis OncolOct 2, 2026 (epub)
Clinical ResearchOncology (Medical)
Maria Vieito, Elena Garralda Cabanas, Inderjit Mehmi et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase II clinical trial evaluated the efficacy and safety of tovorafenib in 23 patients with recurrent/refractory solid tumors harboring BRAF or CRAF fusions/amplifications. The overall response rate was 43%, with 50% in melanoma patients and 40% in other tumors. Tovorafenib was administered at 600 mg weekly.
Key findings
- Overall response rate was 43% (10/23 patients).
- Response rate was 50% (4/8) in melanoma cohort.
- Median duration of response was 9.2 months.
- Most common treatment-related adverse events included anemia (39%) and pruritus (30%).
Why it matters
The study highlights the potential of tovorafenib as a targeted therapy for patients with rare BRAF and CRAF alterations in solid tumors, addressing a significant unmet need in this population.